AI-generated analysis. Always verify with the original filing.
Aquestive Therapeutics entered into Amendment No. 1 to its Purchase and Sale Agreement with RTW funds, extending the Marketing Approval Deadline to June 30, 2027, and concurrently issued a warrant for 375,000 shares at $4.00 per share expiring March 3, 2029, while RTW-affiliated funds committed to purchase at least $5 million of common stock within 90 days. The company also reported Q4 and full year 2025 financial results with total revenues of $13.0 million and $44.5 million, respectively.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On March 3, 2026, Aquestive Therapeutics, Inc. (the "Company") entered into Amendment No. 1 (the "Amendment") to the
by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of, or otherwise subject to the liabilit
Unregistered Sales of Equity Securities. The information set forth in Item 1.01 with respect to the Warrant is incorporated herein by reference. The Warrant is
(including Exhibit 99.2) shall not be deemed to be “filed” for purposes of, or otherwise subject to the liabilities of Section 18 of the Exchange Act, nor shall
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 4.1 Form of Warrant 10.1 Amendment No. 1 to the Purchase and Sale Agreement, dated A
| Metric | Value | Basis |
|---|---|---|
| Total Revenues | $44.50 | GAAP |
| Net Loss | — | GAAP |
Material Agreement